

# **FIVE-YEAR FINANCIAL PLAN**

**Fiscal Years**

**2018-2019-2020-2021-2022**

**2020 Update**

**FOR THE**

## **GENERIC DRUG USER FEE AMENDMENTS**

### **PROGRAM**

**FOOD AND DRUG ADMINISTRATION  
DEPARTMENT OF HEALTH AND HUMAN SERVICES**



**U.S. FOOD & DRUG  
ADMINISTRATION**

## **Table of Contents**

<b>FIVE-YEAR PLAN OVERVIEW</b> .....	<b>3</b>
A. SCOPE.....	3
B. FIVE-YEAR PLAN COMMITMENTS .....	3
C. UPDATES TO THE FIVE-YEAR PLAN.....	3
<b>MANAGEMENT DISCUSSION</b> .....	<b>3</b>
D. ORGANIZATION BACKGROUND.....	3
E. USER FEE BACKGROUND AND STRUCTURE.....	4
F. FORWARD VIEW .....	6
<b>FINANCIAL INFORMATION</b> .....	<b>8</b>
G. USER FEE PROGRAM FINANCIALS .....	8
H. USER FEE REVENUE .....	9
I. USER FEE OBLIGATIONS.....	11
J. USER FEE CARRYOVER.....	12
K. NON-USER FEE APPROPRIATIONS.....	14
L. PLANNED HIRING .....	15
<b>MANAGEMENT ASSURANCE</b> .....	<b>15</b>
M. INTERNAL CONTROLS .....	15
N. RISKS AND CHALLENGES .....	16
<b>APPENDICES</b> .....	<b>18</b>
A. ALLOWABLE AND EXCLUDED COSTS FOR THE GDUFA PROGRAM .....	18
B. USER FEE PROGRAM HISTORY .....	19
C. FINANCIAL NOTES .....	19

## ***Five-Year Plan Overview***

---

### **A. Scope**

The purpose of the Five-Year Financial Plan is to communicate the anticipated financial position of the Generic Drug User Fee Amendments of 2017 (GDUFA II) program over the current five-year authorization period. This document addresses the plan for implementation and use of generic drug user fees by the Food and Drug Administration (FDA or the Agency) during the period of October 1, 2017, through September 30, 2022.

### **B. Five-Year Plan Commitments**

In accordance with *GDUFA Reauthorization Performance Goals and Procedures Fiscal Years FY 2018 Through 2022*, Title VI, Section B, FDA will publish a GDUFA five-year financial plan no later than the second quarter of fiscal year (FY) 2018. FDA will publish updates to the five-year financial plan no later than the second quarter of each subsequent fiscal year. The purpose of this document is to meet these commitments.

### **C. Updates to the Five-Year Plan**

All estimates in the plan are subject to review and reassessment each fiscal year as the actual amounts for appropriations, obligations, and collections for the previous year become available. The five-year financial plan provides the baseline from which future changes will be made. Updates to the five-year financial plan will occur on an annual basis, and cover the 5 years in the current reauthorization period.

## ***Management Discussion***

---

### **D. Organization Background**

FDA is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products and advancing the public's health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get accurate, science-based information needed to use medical products and consume foods to maintain and improve their health. FDA similarly plays a significant role in the nation's counterterrorism capability.

#### **Program Organization**

There are four major FDA components that support the GDUFA program: the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the Office of Regulatory Affairs (ORA), and Headquarters (HQ).

**Exhibit 1** provides an overview of the mission for each of these components.

## Exhibit 1: User Fee Program Components

Component	Mission
CDER	Protects and promotes public health by helping to ensure that human drugs are safe and effective, meet established quality standards, and are available to patients.
CBER	Ensures the safety, purity, potency, and effectiveness of biological products including vaccines, allergenics, blood and blood products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of human diseases, conditions, or injury.
ORA	Protects consumers and enhances public health by maximizing compliance of FDA regulated products and minimizing risk associated with those products.
HQ	Provides FDA-wide program direction and administrative services to ensure FDA's consumer and patient safety programs are effectively and efficiently managed.

### User Fee Governance

The Agency's expanding level of user fees, the reporting of agency performance commitments associated with these fees, and the need for FDA to convey how these fees are executed calls for strong financial governance. This includes an understanding of the design of these programs, clear financial plans, data-driven decisions on resource allocation, consistency and transparency about assumptions, reliable financial forecasting, and accountability for resources spent.

FDA's user fee governance process leverages the User Fee Financial Management Committee, which consists of senior financial, business operations, and program experts across the agency who evaluate user fee resource needs, develop financial allocation plans, and forecast resource requirements – both programmatic and administrative – to support user fee financial decisions. The User Fee Financial Management Committee is responsible for providing oversight and support of appropriate standards and policies to ensure FDA compliance with sound financial management practices, as well as compliance with statutory provisions that authorize FDA to collect and spend user fees. The User Fee Financial Management Committee receives policy guidance and strategic direction directly from the FDA's Executive Committee relative to how the Agency will forecast and react to industry trends, plans and manages its research agenda in support of the user fee programs, and forecasts its user fee workload. The User Fee Financial Management Committee advises the Executive Committee and other Center- and Office-level bodies on a variety of financial and performance related topics.

## E. User Fee Background and Structure

Under GDUFA, FDA collects user fees from human generic drug product manufacturers to fund the generic drug product review process. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by GDUFA, authorizes FDA to collect fees from industry to supplement non-user fee appropriations that the Agency spends on human generic drug activities.

The FDA Reauthorization Act of 2017 (FDARA) includes the reauthorization of GDUFA, also known as GDUFA II, which extends from October 1, 2017 through September 30, 2022. This five-year reauthorization ensures continued funding for FDA from FY 2018 through FY 2022 to support program innovation, evaluation, and improvement. GDUFA II enables FDA to assess user fees to fund critical and measurable enhancements to the performance of FDA's generic drugs program, bringing greater predictability and timeliness to the review of generic drug applications. FDA spends GDUFA user fee collections and non-user fee appropriations to hire, support, and maintain personnel for human generic drug activities to help ensure that safe, effective, and high-quality generic drug products are available to the American public.

Under GDUFA II, some key changes were made to the GDUFA fee structure:

1. The filing fee for a prior approval supplement (PAS) is no longer incurred.
2. No facility or abbreviated new drug application (ANDA) applicant will be charged an annual facility fee until an ANDA is approved.
3. Contract Manufacturing Organizations (CMO) will pay one-third the annual fee paid by firms that manufacture under ANDAs which they or their affiliates own.
4. A person and his or her affiliates will pay one program fee commensurate with the number of approved ANDAs that the firm and its affiliates collectively own.

**Exhibit 2** outlines the GDUFA II user fee structure.

**Exhibit 2: GDUFA II Fee Structure**

Fee Type		Definition
<b>Abbreviated New Drug Application (ANDA)</b>		An ANDA filing fee is incurred upon submission of an abbreviated new drug application.
<b>Program</b>	<i>Small</i>	Each person and his or her affiliates will be assessed an annual fee depending on the number of approved ANDAs in his or her portfolio.
	<i>Medium</i>	
	<i>Large</i>	
<b>Facility</b>	<i>Domestic Active Pharmaceutical Ingredients (API)</i>	An API facility fee is owed by each person who owns a facility that is identified in (1) at least one approved generic drug submission in which the facility is approved to produce one or more APIs or (2) in a Type II API drug master file referenced in at least one approved generic drug submission. An additional \$15,000 is assessed for a facility located outside the United States and its territories and possessions.
	<i>Foreign API</i>	
	<i>Domestic Finished Dosage Form (FDF)</i>	An FDF facility fee is owed by each person who owns a facility that is identified in at least one generic drug submission that is approved to produce one or more finished dosage forms of a human generic drug. An additional \$15,000 is assessed for a facility located outside the United States and its territories and possessions.
	<i>Foreign FDF</i>	
	<i>Domestic Contract Manufacturing Organization (CMO)</i>	An annual CMO facility fee is owed by each person who owns an FDF facility that is identified in at least one approved ANDA, where the facility is not identified in an approved ANDA held by the owner of that facility or its affiliates. An additional \$15,000 is assessed for a facility located outside the United States and its territories and possessions.
	<i>Foreign CMO</i>	
<b>Type II, API Drug Master File (DMF)</b>		The one-time DMF fee is incurred on whichever of the following dates occurs earlier: (1) the first time a generic drug submission references that DMF by an initial letter of authorization on or after October 1, 2012, or (2) the date the DMF holder requests the initial completeness assessment.

The statute specifies how the fees must be calculated each fiscal year, including annual adjustments that must be made for inflation. The fee amounts are to be published in the Federal Register each year; this typically occurs at the beginning of August ([GDUFA User Fee Rates Archive](#)).

GDUFA user fees collected are not a fee-for-service. The user fees that are collected are pooled and may be used for the allowable activities as set forth in the FD&C Act. Refer to **Appendix A** for a detailed list of allowable and excluded activities.

**Appendix B** provides more information on the history of the user fee program.

## **F. Forward View**

### **Discussion of Workload and Other Activities in GDUFA**

GDUFA is a maturing program, now mid-way through its second authorization period. It faces a high workload and unique programmatic and regulatory complexities as it continues to mature. GDUFA I was negotiated under the assumption that FDA would receive 750 new original ANDAs each year. In reality, FDA received an average of approximately 1,000 ANDAs annually throughout GDUFA I. The GDUFA II negotiations assumed 1,000 ANDAs each year. In addition to this increased ANDA volume, the review timeframes in GDUFA II are much more aggressive than in GDUFA I. This increase in workload and the more ambitious goals are the main drivers of the additional funding needs throughout GDUFA II. There exists the potential risk that FDA and industry underestimated the average annual level of ANDA submissions to be received in GDUFA II. A higher number of ANDAs than estimated would require the consumption of additional resources above the planned levels.

FDA is also unable to foresee some trends in the generic drug industry. For example, a great deal of manufacturing has moved overseas in the past few years which has resulted in the need for FDA to conduct more foreign inspections which tend to be more expensive. That expense is offset by the foreign fee differential that overseas manufacturing facilities pay. However, other unpredictable trends in the market could likewise impact FDA's resource consumption.

There are also program enhancements that require increased resources. For instance, there is a new program for complex generic drugs in which FDA provides additional support to applicants in preparing an approvable ANDA. This support helps applicants prepare more complete submissions, which promotes a more efficient and effective ANDA review process and reduces the number of review cycles required to obtain an ANDA approval. CDER's Office of Pharmaceutical Quality (OPQ) conducts research and testing on complex generic drugs to develop a lifecycle research paradigm to proactively identify scientific and technical review challenges posed by complex drug products. This helps reviewers evaluate ANDAs more efficiently by establishing clear standards and methods, improving OPQ's readiness to evaluate applications. In addition, ongoing refinement of the regulatory framework for generic versions of combination products has created additional pre-submission and assessment work related to sameness of device constituent parts and inspections/evaluation of sites that produce device constituent parts for ANDAs. There are also other technology enhancements in development such as OPQ's Knowledge-Aided Assessment & Structured Application (KASA) platform which will enhance lifecycle management of drug products. GDUFA is the first program for which KASA is being developed.

FDA is focused on building staff capacity to manage the increasing program workload, meet performance goals, and deliver on new commitments funded in GDUFA II. The 21<sup>st</sup> Century Cures Act provides new authority to help FDA improve its ability to recruit and retain scientific, technical, and professional experts. This new authority grants FDA the ability to bring on top scientific talent to its review programs at competitive salaries.

### **Efforts to Enhance Financial Management**

GDUFA I was a \$1.5 billion agreement covering 5 years. During the first 2 years of GDUFA I, as the program was being built, FDA spent significantly less than it collected due to a 2 – 3 year lag in meeting staffing needs. Therefore, the carryover balance grew quickly. Eventually, as the program matured, FDA's spending levels increased to exceed its annual collections amounts. Part of the increased spending was due to bringing on term-employees to manage the high pending workload. FDA entered GDUFA II with a carryover balance from GDUFA I, but expected obligations and collections to even out over the course of GDUFA II.

At the end of FY 2019, the carryover balance was \$204,171,168 which would provide for approximately 21 weeks of operations. FDA considers a carryover level to provide for between 8 – 10 weeks as a reasonable amount of carryover to maintain for the GDUFA program. This level of carryover would provide FDA with sufficient reserves to mitigate possible financial risks to the program, such as under collections or a lapse in appropriations.

FDA is assessing opportunities to invest GDUFA resources, including the carryover balance, to support the program. It continues to strive to hire scientific and regulatory staff, while also making targeted strategic investments to enhance productivity, support regulatory science and policy efforts, and ensure the availability of safe and effective generic drug products. FDA will continue working to ensure the financial resource available to the GDUFA program are being invested to support the long-term sustainability and productivity of the review program.

Under GDUFA II, FDA made commitments to establish a resource capacity planning function and to modernize its time reporting approach. CDER and CBER have now implemented modernized time reporting. While it will be several years to fully mature, the resource capacity planning capability will provide the ability to better forecast workload and to translate forecasts into human resource and financial requirements. This capability will help FDA ensure it is optimally deploying the resources available to the GDUFA program.

FDA also made commitments in GDUFA II to enhance efficiency and transparency in the administration of GDUFA's financial resources. This included a third-party evaluation of GDUFA program resource management in FY 2018.<sup>1</sup> It also included the publishing of a five-year plan (this plan), to be updated annually. FDA also held an annual public meeting, the first occurred during FY 2019, which discussed this five-year financial plan, along with the Agency's progress in implementing resource capacity planning, modernized time reporting, and the impact of the user fee structure changes under GDUFA II.<sup>2</sup>

### **Working Capital Fund/Cost Allocation**

FDA has a Cost Allocation and Recovery framework to improve financial management of user fee resources for GDUFA, the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA). Congress authorized FDA to establish a Working Capital Fund (WCF) to finance centralized services (see P.L. 115-141). The WCF benefits the financial management of Agency funds by:

- Increasing transparency through defining administrative activities performed for Centers and Offices and allocating costs based on Agency usage.
- Strengthening accountability by improving the tracking and management of administrative costs, including costs charged to user fees for administrative services.
- Promoting efficiency by optimizing customer usage and improving the management of user fee administrative costs over time.
- Leveraging the WCF governance structure to ensure FDA leadership engagement in decision making relative to administrative costs, efficiency opportunities, recapitalization, and burden on all funding sources – including user fees.

---

<sup>1</sup> <https://www.fda.gov/drugs/development-resources/fiscal-year-2018-financial-management-evaluation-human-drug-user-fees-assessment-report>

<sup>2</sup> <https://www.fda.gov/drugs/news-events-human-drugs/financial-transparency-and-efficiency-prescription-drug-user-fee-act-biosimilar-user-fee-act-and>

## Financial Information

This section provides an overview of the projected financial outlook for GDUFA through the FY 2018 – FY 2022 reauthorization period. These projections include user fee revenue, obligations, carryover, non-user fee appropriations requirements, and planned hiring. The forecasts included in this section are driven by the initiatives and goals as outlined in the Forward View section of this plan. Refer to prior year GDUFA Five-Year Financial Plans for additional information on prior year estimates.<sup>3</sup>

### G. User Fee Program Financials

**Table 1** represents a summary of the forecasted GDUFA financial position, as it relates to user fee resources (collections and carryover). This table also provides an overview of planned obligations for which the user fee resources would be used. Future updates to this plan will supplement the financial estimates with actual amounts received, obligated, and carried over for the past fiscal years. The financial notes can be found in **Appendix C**

**Table 1: Human Generic Drug Collections, Obligations, and Carryover for Fiscal Year 2018 through Fiscal Year 2022**

Budgetary Resources	Notes	FY 2018	FY 2019		FY 2020	FY 2021	FY 2022
		Actual	Estimate	Actual	Estimate	Estimate	Estimate
<b>Target Revenue</b>	Note 1	<b>\$493,600,000</b>	<b>\$501,721,000</b>	<b>\$501,721,000</b>	<b>\$513,223,000</b>	<b>\$525,714,000</b>	<b>\$538,510,000</b>
Cash Collections		\$493,655,974	\$501,721,000	\$496,503,494	\$513,223,000	\$525,714,000	\$538,510,000
Recoveries	Note 2	\$4,920,184	\$4,000,000	\$8,544,957	\$5,000,000	\$5,000,000	\$5,000,000
Carryover Available for Use, Beginning of Year		\$137,412,048	158,715,667 <sup>†</sup>	\$158,715,667	\$199,171,168 <sup>†</sup>	\$166,138,068	\$137,560,699
<b>Total Budgetary Resources</b>		<b>\$635,988,205</b>	<b>\$664,436,667</b>	<b>\$663,764,117</b>	<b>\$717,394,168</b>	<b>\$696,852,068</b>	<b>\$681,070,699</b>

Obligations	Notes	FY 2018	FY 2019		FY 2020	FY 2021	FY 2022
		Actual	Estimate	Actual	Estimate	Estimate	Estimate
Total Payroll and Operating	Note 3	\$397,961,320	\$408,501,495	\$384,721,323	\$466,571,225	\$473,759,645	\$468,721,449
Total Rent	Note 4	\$22,019,962	\$25,795,102	\$24,962,969	\$26,053,053	\$26,313,583	\$26,576,719
Total Shared Services	Note 5	\$57,291,257	\$54,723,889	\$54,908,657	\$58,631,822	\$59,218,140	\$59,810,322
<b>Total Obligations</b>		<b>\$477,272,539</b>	<b>\$489,020,486</b>	<b>\$464,592,949</b>	<b>\$551,256,100</b>	<b>\$559,291,369</b>	<b>\$555,108,489</b>

Carryover	Notes	FY 2018	FY 2019		FY 2020	FY 2021	FY 2022
		Actual	Estimate	Actual	Estimate	Estimate	Estimate
Total Carryover, End of Year		\$163,715,667	\$180,416,181	\$204,171,168	\$171,138,068	\$142,560,699	\$130,962,210
Carryover Unavailable for Use, End of Year		(\$5,000,000)	(\$5,000,000)	(\$5,000,000)	(\$5,000,000)	(\$5,000,000)	(\$5,000,000)
<b>Carryover Available for Use, End of Year</b>		<b>\$158,715,667</b>	<b>\$175,416,181</b>	<b>\$199,171,168</b>	<b>\$166,138,068</b>	<b>\$137,560,699</b>	<b>\$125,962,210</b>

Target Revenue has been rounded to the nearest thousand dollars

All other numbers have been rounded to the nearest dollar

<sup>†</sup>Indicates an actual amount

**Budgetary Resources:** The budgetary resources component of **Table 1** illustrates the FY 2018 and FY 2019 actuals and the forecast for FY 2020 through FY 2022 for the sum of available user fee funding (i.e.,

<sup>3</sup> <https://www.fda.gov/about-fda/user-fee-reports/user-fee-five-year-financial-plans>

the existing carryover balance available for use and additional projected user fee collections) that will be used to fund obligations. The target revenue is the annual revenue amount established when fees for the fiscal year are set. Cash collections are the actual amount collected during the fiscal year and are forecasted to be equal to the target revenue. GDUFA II specifies how the fees must be calculated each fiscal year, including annual adjustments that must be made for inflation.

For the purposes of this plan, future year recoveries are estimated to be \$5,000,000 annually. Additional details on recoveries are included in **Note 2**.

**Obligations:** The obligations component of **Table 1** shows the FY 2018 and FY 2019 actual expenditure and planned annual expenditure for FY 2020 through FY 2022 of GDUFA fee funds broken out into major expense categories. GDUFA fees may be expended only for costs to support “human generic drug activities,” as defined in GDUFA II.

**Carryover:** GDUFA fees are available until expended. This means that the fees that are collected, appropriated, and not obligated at the end of the fiscal year remain available to FDA for use in future fiscal years. The unobligated GDUFA funds at the end of each fiscal year are referred to as the “carryover balance” of **Table 1**. Maintaining an appropriate level of carryover enables FDA to mitigate financial risks to the program, including for example, the risk of under collecting fees and the risk of a lapse in appropriations.

## H. User Fee Revenue

**Table 2** outlines the estimated annual target revenue amounts for each fiscal year. The financial notes referenced in this table can be found in **Appendix C**.

FDA assumes, for planning purposes, that cash collections will equal the target revenue amount. Cash collections may differ from the annual target revenue amount if the actual number of fee-paying units differ from the number of fee-paying units estimated when fees are set each year.

Annual updates to this plan will update the actual target revenue amounts for the current fiscal year and the actual collections amount from the preceding fiscal year.

**Table 2: Human Generic Drug Revenue and Collections Statement for Fiscal Year 2018 through Fiscal Year 2022**

Target Revenue	Notes	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
		Actual	Actual	Actual	Estimate	Estimate
Statutory Base		\$493,600,000	\$493,600,000	\$501,721,201	\$513,223,160	\$525,714,498
Inflation Adjustment		\$0	\$8,121,201	\$11,501,959	\$12,491,338	\$12,795,365
<b>Target Revenue Total</b>	<b>Note 1</b>	<b>\$493,600,000</b>	<b>\$501,721,000</b>	<b>\$513,223,000</b>	<b>\$525,714,000</b>	<b>\$538,510,000</b>

Target Revenue has been rounded to the nearest thousand dollars

Budgetary Resources	Notes	FY 2018	FY 2019		FY 2020	FY 2021	FY 2022
		Actual	Estimate	Actual	Estimate	Estimate	Estimate
Cash Collections		\$493,655,974	\$501,721,000	\$496,503,494	\$513,223,000	\$525,714,000	\$538,510,000
Recoveries	Note 2	\$4,920,184	\$4,000,000	\$8,544,957	\$5,000,000	\$5,000,000	\$5,000,000
Carryover Available for Use, Beginning of Year		\$137,412,048	\$158,715,667 <sup>†</sup>	\$158,715,667	\$199,171,168 <sup>†</sup>	\$166,138,068	\$137,560,699
<b>Total Budgetary Resources</b>		<b>\$635,988,205</b>	<b>\$664,436,667</b>	<b>\$663,764,117</b>	<b>\$717,394,168</b>	<b>\$696,852,068</b>	<b>\$681,070,699</b>

Numbers have been rounded to the nearest dollar

<sup>†</sup>Indicates an actual amount

The base revenue for FY 2018 is specified in statute. The base revenue for each subsequent year is equal to the prior year’s base plus inflation.

The process for setting the annual target revenue is defined in statute. Each year’s base revenue is adjusted for inflation, as described below:

- **Inflation Adjustment:** The inflation adjustment adjusts the base amount to maintain the purchasing power of fee funds in consideration of inflation. The adjustment is a composite measure that weights operating expenses by changes in the Consumer Price Index (CPI) and payroll-related expenses by changes in FDA’s average personnel compensation and benefits amounts.

The inflation adjustment for future years, for the purposes of this plan, is estimated by using the Federal Reserve Bank of Cleveland’s CPI projections, as well as historical averages of the changes in FDA’s average salary and benefits amounts.

There was no inflation adjustment in FY 2018; the actual inflation adjustment utilized in FY 2019 and FY 2020 was 1.6453 and 2.2925 percent (rounded) respectively. The inflation adjustment for FY 2021 and FY 2022 is estimated at 2.4339 percent.

Unlike PDUFA or BsUFA, GDUFA does not provide for a capacity planning adjustment to adjust the annual target revenue based on changes in workload. As such, increases in ANDAs will lead to a lower fee amount in future years, while FDA will be expected to maintain the same level of performance at the higher workload level, without a commensurate increase in fee revenues to fund the additional needed staffing.

Fee rates are established each year so that revenues from ANDA fees provide 33 percent of the total revenue, DMF fees provide 5 percent of the total revenue, FDF and CMO facility fees provide 20 percent of the total revenue, API facility fees provide 7 percent of the total revenue, and GDUFA program fees provide 35 percent of the total revenue. User fee collections are recognized and reported in the year the fee was originally due (referred to as the “cohort year”). Totals reported for each fiscal year are net of any refunds for the cohort year.

**Table 3** presents the forecasted and actual total annual collections by fee type and cohort year.

**Table 3: GDUFA II Collections**

Fee Type	Cohort Year 2018	Cohort Year 2019		Cohort Year 2020	Cohort Year 2021	Cohort Year 2022
	Actual	Estimate	Actual	Estimate	Estimate	Estimate
ANDA Fees	\$168,644,366	\$165,567,930	\$160,389,460	\$169,363,590	\$173,485,620	\$177,708,300
DMF Fees	\$22,718,775	\$25,086,050	\$23,703,419	\$25,661,150	\$26,285,700	\$26,925,500
Facility Fees (FDF, CMO, and API)	\$147,283,511	\$135,464,670	\$149,315,961	\$138,570,210	\$141,942,780	\$145,397,700
Program Fees	\$144,443,886	\$175,602,350	\$178,395,663	\$179,628,050	\$183,999,900	\$188,478,500
<b>Total Cash Collections</b>	<b>\$483,090,538</b>	<b>\$501,721,000</b>	<b>\$511,804,503</b>	<b>\$513,223,000</b>	<b>\$525,714,000</b>	<b>\$538,510,000</b>

Estimated Total Cash Collections have been rounded to the nearest thousand dollars

All other numbers have been rounded to the nearest dollar

## I. User Fee Obligations

**Table 4** provides a breakout of planned user fee obligations by expense category for the 5 years represented in this plan. The annual updates to this plan will provide actual amounts for the preceding fiscal year, as well as updated planned amounts for the remaining fiscal years. The financial notes can be found in **Appendix C**.

**Table 4: Human Generic Drug User Fee Obligations by Expense Category for Fiscal Year 2018 through Fiscal Year 2022**

User Fee Obligations	Notes	FY 2018	FY 2019		FY 2020	FY 2021	FY 2022
		Actual	Estimate	Actual	Estimate	Estimate	Estimate
Payroll & Operating	Note 3						
CBER		\$49,462	\$982,344	\$23,658	\$1,004,864	\$1,029,321	\$1,054,374
CDER		\$323,591,582	\$323,783,061	\$316,437,772	\$370,219,339	\$379,203,830	\$382,105,904
ORA		\$46,518,651	\$47,841,387	\$40,694,363	\$50,938,151	\$50,129,256	\$51,349,352
HQ		\$27,801,624	\$35,894,703	\$27,565,531	\$44,408,872	\$43,397,237	\$34,211,819
Total Rent	Note 4	\$22,019,962	\$25,795,102	\$24,962,969	\$26,053,053	\$26,313,583	\$26,576,719
Total Shared Services	Note 5	\$57,291,257	\$54,723,889	\$54,908,657	\$58,631,822	\$59,218,140	\$59,810,322
<b>Total Obligations</b>		<b>\$477,272,539</b>	<b>\$489,020,486</b>	<b>\$464,592,949</b>	<b>\$551,256,100</b>	<b>\$559,291,369</b>	<b>\$555,108,489</b>

Numbers have been rounded to the nearest dollar

Total obligations include payroll and operating, rent, and shared services costs. The details of each component of total obligations are as follows:

- Payroll and Operating:** These obligations provide for all payroll and operating costs that support the allowable activities for which GDUFA fees may be expended, as set forth in statute. This includes, for example, core regulatory review functions, pre-approval inspections, guidance and policy development activities, scientific activities, science and research activities, and management and administrative functions that support the GDUFA program. **Appendix A** provides additional information regarding allowable and excluded costs for the GDUFA program.
- Rent:** This is paid to the General Services Administration (GSA) for the Federal buildings that FDA occupies, as well as to non-Federal sources for direct leases and services (see Note 4). Rent is charged at different rates depending on the type and location of the space provided.

The future year amounts, for the purposes of this plan, are assumed to have an increase of 1 percent yearly.


- Shared Services:** FDA has several shared service organizations that provide support across the user fee programs, such as human resources and IT. Shared services at FDA are located within the WCF. The future year amounts, for the purposes of this plan, are assumed to have an increase of 1 percent yearly. Yearly costs are determined by the Cost Allocation and Recovery framework discussed previously. In FY 2020, the WCF absorbed several offices that were previously located within HQ. This change is responsible for the variance in HQ and Shared Services from the original plan, published in FY 2018, for FY 2020 and beyond. **Note 5** provides a full list of the what is contained in the WCF.

Variations occurred between the original FY 2019 plan and the actuals in some areas:

- **CBER Obligations:** Actual CBER obligations in FY 2019 were lower than estimated due to a lower amount of workload than anticipated. GDUFA funding will not be utilized unless the workload at the Center requires it.
- **HQ Obligations:** Actual HQ obligations were lower in FY 2019 due to transfers into the WCF as well as returns from specific offices that were unable to hire. These offices will continue to make efforts to bring new hires on board.
- **ORA Obligations:** Actual ORA obligations in GDUFA were lower than anticipated due to hiring challenges and lower than estimated payroll needs. ORA continues to work to bring hires on board.

For historical context, **Exhibit 3** provides an illustration of historical GDUFA I obligations and projected GDUFA II needs.

**Exhibit 3: Historic and Forecasted User Fee Obligations by Fiscal Year**



As demonstrated by this graph, the overall trend has been increasing in program needs over the past 7 years. This increase in needs is primarily driven by a greater than expected volume of ANDA submissions and associated workload along with program enhancements, and hiring of staff to manage the program workload.

## J. User Fee Carryover

GDUFA fees collected, appropriated, and not obligated at the end of the fiscal year remain available to support the GDUFA program in future fiscal years. This balance is referred to as the GDUFA carryover.

Maintaining an appropriate level of carryover enables FDA to mitigate financial risks to the program, including for example, the risk of under collecting fees and the risk of a lapse in appropriations. For the GDUFA program, FDA considers an amount equivalent to between 8 – 10 weeks of operations (\$82.8 million – \$103.6 million in FY 2022) to be a reasonable amount of carryover. In addition, the authorizing statute provides for a Final Year Adjustment in FY 2022 to increase fees to provide for up to 3 months of operations.

See the Forward View section of this plan for additional discussion of the carryover balance.

The carryover balance includes two categories:

- **Carryover Unavailable for Use** – This value represents carryover funds subject to claims or restrictions that precludes FDA from obligating the carryover funds.
- **Carryover Available for Use** – This value represents carryover funds that are not subject to any claims or restrictions and are therefore available for obligation.

The net change in carryover balance each year is equal to cash collections minus net obligations. This is shown in **Table 1** above.

**Table 5** provides projections of GDUFA carryover balances at the end of each fiscal year. Forecasted estimates will be updated with actual amounts in future Five-Year Financial Plan annual updates. The financial notes can be found in **Appendix C**.

**Table 5: GDUFA Carryover by Fiscal Year**

Carryover	Notes	FY 2018	FY 2019		FY 2020	FY 2021	FY 2022
		Actual	Estimate	Actual	Estimate	Estimate	Estimate
<b>Total Carryover, End of Year</b>		\$163,715,667	\$180,416,181	\$204,171,168	\$171,138,068	\$142,560,699	\$130,962,210
Refunds	Note 6	(\$5,000,000)	(\$5,000,000)	(\$5,000,000)	(\$5,000,000)	(\$5,000,000)	(\$5,000,000)
<b>Carryover Available for Use, End of Year</b>		\$158,715,667	\$175,416,181	\$199,171,168	\$166,138,068	\$137,560,699	\$125,962,210


Numbers have been rounded to the nearest dollar

To determine how much carryover is available for obligation at the end of a fiscal year, the following factors must be considered:

- **Total Carryover, End of Year** – This is the total amount of unobligated funds at the end of the fiscal year.
- **Carryover Unavailable for Use, End of Year** – As noted above, this value includes unobligated fee funds subject to any claims or restrictions on fees collected. This includes:
  - **Refunds** – FDA maintains a small amount to provide for any refunds, as a matter of prudent operations. For that purpose, a total of \$5,000,000 is being set aside. See **Note 6** for additional details.
- **Carryover Available for Use, End of Year** – As noted above, this is the total carryover less any carryover unavailable for use. These funds become the carryover available for use at the beginning of the next fiscal year.

**Exhibit 4** below shows the historic trend of carryover in GDUFA II and the forecasted carryover in GDUFA II.

**Exhibit 4: Historic and Forecasted Carryover by Fiscal Year**



FDA will continue to monitor the carryover balance and the factors that influence it, to mitigate risks such as collection shortfalls or lapses in appropriations.

**Carryover Reduction**

Carryover available for use is expected to be reduced from \$199,171,168 at the end of FY 2019 to \$125,962,210 at the end of FY 2022.

## K. Non-User Fee Appropriations

For FDA to obligate user fees collected under GDUFA, a certain amount of non-user fee appropriations must be spent on human generic drug activities during that fiscal year. This is often referred to as a “non-user fee spending trigger”.<sup>4</sup>

**Table 6** presents the actual non-user fee spending triggers for FY 2018, FY 2019, FY 2020, and the forecasted non-user fee spending triggers for FY 2021 and FY 2022.

**Table 6: Minimum Allocation of GDUFA Non-User Fee Appropriations by Fiscal Year**

FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Actual	Actual	Actual	Estimate	Estimate
\$103,558,073	\$105,671,800	\$108,337,360	\$110,078,219	\$111,834,404

Numbers have been rounded to the nearest dollar

The non-user fee spending trigger amount is determined by multiplying the base amount of non-user fee appropriations spent on human generic drug activities (\$97,000,000) times the adjustment factor for the fiscal year. See **Note 7** for more details on the adjustment factor.

FDA is committed to spend at least the required minimum from non-user fee appropriations each fiscal year. In years when FDA programs do not receive appropriations to cover costs of inflation and mandatory pay increases, FDA activities other than generic drug review may be reduced to assure that the allocation of non-user fee appropriations for generic drug reviews meets the requirements of this trigger.

<sup>4</sup> The GDUFA program requires a minimum spending from appropriations, excluding user fees. The minimum spending from appropriations is \$97,000,000 multiplied by the adjustment factor defined in section 744A(3) applicable to the fiscal year involved.

## L. Planned Hiring

FDA has developed a plan to bring on a total of 95 full-time equivalents (FTE) consisting of both Federal and contract staff. These additional resources will enable the Agency to continue meeting the goals outlined in the commitment letter and will also utilize carryover balances. To date, FDA has filled 40 of these positions and is working to bring on additional resources in FY 2020. Updates on planned hiring will be provided in subsequent annual reports.

## ***Management Assurance***

---

### M. Internal Controls

The Federal Managers' Financial Integrity Act (FMFIA) of 1982 is intended to strengthen internal controls and accounting systems. The Office of Management and Budget (OMB) Circular No. A-123, *Management's Responsibility for Internal Control and Enterprise Risk Management* (OMB A-123), implements the requirements of the FMFIA. The FMFIA requires that management establish and maintain effective internal control to achieve the objectives of:

1. Effective and efficient operations,
2. Reliable financial reporting, and
3. Compliance with applicable laws and regulations.

The Department of Health and Human Services (HHS) provides guidance to its operating divisions (OpDivs) to implement FMFIA through its FMFIA Guidelines. OpDivs, including FDA, are responsible for developing and maintaining a cost-effective internal control and compliance program that includes programmatic and operational controls, as well as controls over financial reporting, and supports sound financial management. The Government Accountability Office (GAO) *Standards for Internal Control in the Federal Government* (Green Book) states, "Management is responsible for an effective internal control system. As part of this responsibility, management sets the entity's objectives, implements controls, and evaluates the internal control system." OMB A-123 requires an annual internal control assessment, and FMFIA requires the head of each executive agency to report annually to the President and Congress on the effectiveness of the internal controls and any identified material weaknesses in those controls. FDA's FY 2019 Assurance Statement, already submitted to HHS, found no material weaknesses or financial system nonconformances.

Additionally, FDA has established a Senior Assessment Team (SAT) as the governance body responsible for providing oversight and accountability for FDA's internal control over financial reporting, including overseeing the FMFIA and A-123 assessments to foster an environment that promotes strong internal control. The SAT is chaired by the FDA Chief Financial Officer (CFO) and co-chaired by the Deputy CFO and Director of the Office of Financial Management, as well as a Program Co-Chair who is a Center Deputy Executive appointed by the CFO. The SAT members are representatives from each FDA Center and Office.

In accordance with FMFIA, OMB A-123, the Green Book, and HHS guidelines, FDA has a robust internal control program, including integrated controls throughout processes. The Agency also conducts an annual assessment of its internal control activities as well as operational risk reviews. In addition, FDA has an Enterprise Risk Management (ERM) Program, which began in earnest in FY 2016 and is integrated with FDA's FMFIA efforts. Under the ERM program, FDA has refreshed the enterprise risk profile and facilitated risk response planning for five priority enterprise risks. To accomplish this, Centers and Offices are engaged through senior leadership interviews, as well as working groups and problem-

solving sessions. Further, FDA has established an ERM Community of Practice, and continues to align and integrate core ERM methodologies with those of internal controls. FDA's ERM program has facilitated cross-Center and Office collaboration to identify and manage risks. It is governed by the ERM Council, which is chaired by the Chief Operating Officer and the CDER Deputy Director for Operations.

FDA's internal control program includes an evaluation of controls over reporting, charge card compliance, improper payments, and financial systems compliance. One of the cycle memos included in the assessment scope includes internal controls over reporting for the reimbursable activity process, specifically focused on the Accounts Receivable and Payment process associated with the user fee programs. This includes controls over reconciliation performance, aging, write-offs, and the interface between the User Fee System and the Unified Financial Management System. As an FDA-owned system, FDA's User Fee System is compliant with HHS requirements and requirements of the Federal Financial Management Improvement Act (FFMIA) of 1996. In addition, FDA's Integrated Budget and Acquisition Planning System (IBAPS) meets FDA and HHS system requirements.

FDA is also a participant in the annual audit of the consolidated financial statements of HHS, including the consolidated balance sheet, the related consolidated statement of net costs and changes in net position, the combined statement of budgetary resources, and the related notes to the financial statements. The FY 2019 audit found that the financial statements present fairly, in all material respects, the consolidated financial position of HHS as of September 30, 2019 and 2018, and its consolidated net cost, changes in net position, budgetary resources, and related notes are in accordance with U.S. generally accepted accounting principles.

FDA has also implemented other internal control procedures, including a continuous monitoring program to oversee the timely implementation of corrective action plans for deficiencies identified through any of its control assessments. This continuous monitoring program allows for management oversight of targeted remediation efforts and strengthening of internal controls. In addition, FDA offers annual internal control training sessions, which cover the importance of internal controls, timely deficiency remediation, and roles and responsibilities.

## **N. Risks and Challenges**

### **Financial Risks and Mitigation**

As is the case with all financial programs, there are certain financial risks and challenges that exist with FDA's user fee programs. These risks and challenges can vary from program to program, with some being in FDA's control and some out of FDA's control. An example of a shared financial risk across all user fee programs is that FDA cannot obligate funds in advance of receiving the funds, either through appropriated user fee collections or non-user fee appropriations. FDA can only assume what the Agency's total appropriation will be in any given year. As a result, FDA has some risk of missing important performance goals, or failing to meet the non-user fee spending trigger for the fiscal year, if that total appropriation comes in considerably lower than anticipated. Below is a listing of foreseeable risks associated with the collections and obligations of funds for which FDA has identified contingency plans in order to move forward in the best interests of the program.

- **Under-Executing Planned Spend:** GDUFA budgetary resources have been under-spent due to the uncertainty around the timing of revenue (user fee and non-user fee) availability, non-user fee spending trigger requirements, and difficulties with hiring. To minimize this risk, FDA continued to enhance its planning and execution around the hiring of new staff and contract actions in the second year of the reauthorization. By putting more emphasis on the initial

planning of initiatives, FDA predicts that there will be less variance while comparing planned allocations to actual expenditures than FDA has experienced in the past.

- **Uncertainty of Non-User Fee Appropriations Levels:** It is difficult to predict the amount of non-user fee appropriations that will be approved by Congress, which creates planning challenges as non-user fee fund levels are often uncertain for much of the fiscal year. With Continuing Resolutions (CR) becoming more prevalent, FDA has been required to spend at or slightly below levels from the prior authorized fiscal year during the CR period, thus limiting its ability to spend the non-user fee appropriations from the onset.
- **Lapse in Non-User Fee Appropriations:** FDA is maintaining a certain level of carryover, which can be used to preserve program operations for a limited time in the event of a shutdown. For the GDUFA program FDA believes it needs roughly 8 to 10 weeks of carryover to help mitigate this risk.
- **Under Collecting and Over-Collecting:** If FDA does not receive the estimated number of fee-paying units, there may be an excess or deficit in targeted revenue. When FDA under collects user fees, it leverages its carryover balance to maintain continuity in operations. When FDA over collects, the carryover may increase without additional planned expenditures being identified towards which to obligate those funds. In addition, FDA monitors collections throughout the fiscal year, and the User Fee Financial Management Committee and other FDA senior leaders determine how to mitigate any instances when user fee revenue deviates from forecasted estimates. Net collections during GDUFA II have been very close to planned collection (target revenue).

In addition to these mitigation strategies, FDA implemented Integrated Budget and Acquisition Planning System (IBAPS) to enable greater and more timely insight into budget activity across the Agency. IBAPS improves the accuracy and availability of budget and acquisition information that enables FDA to better plan, forecast, track, and analyze the data to make better informed decisions about the best use of its resources.

### **Strategic Challenges**

FDA acknowledges that anticipated workload is the greatest unknown and most impactful variable throughout GDUFA II. If industry and FDA can accurately predict submission volumes, then the financial management of the program will avoid similar challenges it faced in GDUFA I. If, however, the volume of submissions, including original applications, amendments, and supplements, is greater than expected, the program will face workload and staffing challenges over the remainder of GDUFA II since FDA does not have a mechanism to increase revenue to keep pace with sustained increases in workload during GDUFA II.

# Appendices

## A. Allowable and Excluded Costs for the GDUFA Program

Section 744A(9) of the FD&C Act defines in general, the term “human generic drug activities” as the activities associated with generic drugs and inspection of facilities associated with generic drugs. In summary, costs related to the following have been attributed to human generic drug activities:

Included Activities	
<ol style="list-style-type: none"> <li>1. The activities necessary for the review of generic drug submissions, including review of DMFs referenced in such submissions.</li> <li>2. The issuance of—               <ol style="list-style-type: none"> <li>a. Approval letters which approve ANDAs or prior approval supplements to such applications.</li> <li>b. Complete response letters which set forth in detail the specific deficiencies in such applications and, where appropriate, the actions necessary to place such applications in condition for approval.</li> </ol> </li> <li>3. The issuance of letters related to Type II active pharmaceutical ingredient DMFs which:               <ol style="list-style-type: none"> <li>a. Set forth in detail, the specific deficiencies in such submissions, and where appropriate, the actions necessary to resolve those deficiencies; or</li> <li>b. Document that no deficiencies need to be addressed.</li> </ol> </li> <li>4. Inspections related to generic drugs.</li> <li>5. Monitoring of research conducted in connection with the review of generic drug submissions and DMFs.</li> </ol>	<ol style="list-style-type: none"> <li>6. Post-market safety activities with respect to drugs approved under abbreviated new drug applications or supplements, including the following activities:               <ol style="list-style-type: none"> <li>a. Collecting, developing, and reviewing safety information on approved drugs including adverse event reports.</li> <li>b. Developing and using improved adverse-event data collection systems, including information technology systems.</li> <li>c. Developing and using improved analytical tools to assess potential safety problems including access to external databases.</li> <li>d. Implementing and enforcing section 505(o) (relating to post-approval studies and clinical trials and labeling changes) and section 505(p) (relating to risk evaluation and mitigation strategies) insofar as those activities relate to abbreviated new drug applications.</li> <li>e. Carrying out section 505(k)(5) (relating to adverse-event reports and post-market safety activities).</li> </ol> </li> <li>7. Regulatory science activities related to generic drugs.</li> </ol>

Section 744A(12) of the FD&C Act defines the term “resources allocated for human generic drug activities” as expenses for the following:

Included Expenses
<ol style="list-style-type: none"> <li>1. Officers and employees of FDA, contractors of FDA, advisory committees, and the costs related to such officers, employees, and committees, and to contracts with such contractors;</li> <li>2. Management of information and the acquisition, maintenance, and repair of computer resources;</li> <li>3. Leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; and</li> <li>4. Collecting fees under subsection 744B of the FD&amp;C Act and accounting for resources allocated for the review of abbreviated new drug applications and supplements and inspection related to generic drugs.</li> </ol>

The GDUFA program excludes costs related to the following:

Excluded Activities
1. All activities necessary for the review of new drug applications (NDAs), biologic license applications (BLAs), and investigational new drugs (INDs) for drugs that will not be approved under ANDAs.
2. The issuance of correspondence unrelated to abbreviated new drug submissions, pre-ANDAs, or prior approval supplements.
3. Inspections unrelated to human generic drugs.
4. Monitoring of research unrelated to human generic drug submissions and DMFs.
5. Post-market safety activities apart from those drugs approved under ANDAs or supplements.

## B. User Fee Program History

The FD&C Act, as amended by GDUFA, authorizes FDA to collect user fees from the generic drug product industry to supplement the non-user fee appropriations that the Agency spends on human generic drug activities. FDA spends fee revenues and non-user fee appropriations to hire, support, and maintain personnel for the generic drug review program to ensure the American public has access to safe and high-quality generic drugs and generic drug products.

Originally authorized in [2012](#), GDUFA was reauthorized by FDARA in 2017 (GDUFA II) with the support of the generic drug industry, public stakeholders, Congress, and the Administration.

## C. Financial Notes

### Note 1. Annual Target Revenue Methodology

The estimated user fee collections over the five-year period represented by this plan are based on the target revenue (i.e., base revenue adjusted for inflation).

### Note 2. Recoveries

Recoveries account for funds returned to the Agency in the form of deobligations of prior year obligations. For example, recoveries could include funding from a contract that ended in a prior year and was not expended.

### Note 3. Pay and Operating Costs

Pay and operating costs associated with the GDUFA program are based on obligations attributed to CBER, CDER, ORA and HQ.

For payroll, employees are required to report their time in an activity-based reporting system, which allows FDA to identify activities that user fees can be used to support. See **Appendix A** for a listing of those activities. For operating activities (e.g., contracting services), funds are allocated based on the proportion to which those activities support the GDUFA program. If an operating activity solely supports GDUFA, it will be fully funded by the program. If the operating activity is shared, GDUFA will fund the activity in proportion to how it is used by the program as compared to other programs.

### Note 4. Rent Costs

The GSA charges rent to FDA for the Federal buildings that FDA occupies. This rent is charged at different rates depending on the type and location of the space provided. Since rent is an essential

support cost for human generic drug activities, a portion of those charges is paid from non-user fee appropriations and a portion is paid from GDUFA fees. Also included in this account are recurring costs that FDA pays to non-Federal sources under the delegation of direct lease and service authority. These services include rental of space, and all recurring services for building operations such as overtime utilities, janitorial services, guards, and ground maintenance. The amount of rent and rent related costs each Center pays is directly related to the number of employees that must be housed.

#### **Note 5. Shared Service Costs**

FDA several shared service organizations, located with the WCF, that provide support across the user fee programs. Several new organizations joined the WCF in FY 2020. The shared service organizations in FY 2020 include:

- **FDA Central:** Provides for Center-wide and Agency-wide services such as telecommunications, training, printing, mail and document management, IT systems, employee health units, and other support and miscellaneous services.
- **Employee Resource & Information Center (ERIC):** Provides support to all FDA employees requesting administrative, IT, facilities, human resources, and other employee services.
- **Office of Acquisitions and Grants Services (OAGS):** Manages contracts, grants, and other agreements.
- **Office of Equal Employment Opportunity (OEEO):** Promotes an inclusive work environment that ensures equal employment opportunity, and fosters a culture that values diversity and empowers individuals.
- **Office of Facilities, Engineering, and Mission Support Services (OFEMS):** Provides FDA employees with office and laboratory facilities.
- **Office of Financial Management (OFM):** Provides financial managerial services and policy guidance.
- **Office of Information Management and Technology (OIMT):** Provides the information, communication, and knowledge infrastructure and services that enhance, transform, and sustain the ability of FDA to protect and promote the public health.
- **Division of Budget Execution and Control (DBEC):** Initiates, monitors and analyzes FDA budget resources. The agency budget is comprised of several appropriation accounts including: Salaries and Expenses, Revolving Fund for Color Certification and other Services, Cooperative Research and Development Agreement, Contingency Fund, Building and Facilities, and Royalties.
- **Office of External Affairs – History:** Provides research, documentation, and preservation of significant FDA historical resources, as well as serving as historian for the Agency.
- **Office of Security Operations (OSO):** Develops and implements the Agency-wide security policies and programs by providing leadership and guidance to managers and staff on all aspects of security. Administers vital security functions that contribute to the Agency’s mission of protecting the public health by enhancing the safety and security of all personnel, facilities, and information.
- **Paperwork Reduction Act (PRA):** Acts as the liaison between FDA Centers, HHS, and OMB on all information collection matters.
- **Office of Laboratory Science and Safety (OLSS):** OLSS reinforces FDA’s expectations for safety and laboratory security, enhances communications among FDA safety staff, and provides program support.
- **Office of Ethics and Integrity (OEI):** Protects the integrity of FDA’s programs and operations by promoting an ethical culture and ensuring compliance with applicable federal ethics laws.
- **Office of Enterprise Management Services (OEMS):** Informs operational objectives and guides strategic management planning to facilitate increased Agency effectiveness and efficiency.

- **Program Alignment Team (PAT):** Provides advice and guidance on reorganizations and delegations of authority.
- **Office of Human Capital Management (OHCM):** Provides Human Resource services which promote collaboration and a work environment that is characterized by diversity, fairness, open communication, personal accountability, trust and mutual respect.
- **Office of Talent Solutions (OTS):** To provide high quality and efficient Human Resource solutions that enable the FDA to hire a talented and qualified workforce.

#### **Note 6. Refunds**

If an ANDA is considered not to have been received within the meaning of section 355(j)(5)(A) for a cause other than failure to pay user fees, or if the ANDA is withdrawn prior to being received within the meaning of section 355(j)(5)(A), the applicant is eligible for a 75 percent refund of the ANDA filing fee. If an ANDA is initially received under section 355(j)(5)(A), but FDA subsequently determines that the exclusivity period for a listed drug should have prevented the ANDA from being received, the ANDA is no longer considered received under section 355(j)(5)(A), and the applicant is eligible for a full refund of the ANDA filing fee paid.

Refunds impact net fee collections for each fiscal year. Cash collections reflect the amount of fees collected net any refunds or adjustments that occurred during that fiscal year.

#### **Note 7. Appropriations Adjustment Factor**

FDA must calculate and incorporate adjustment factors (defined in section 744A(3) of the FD&C Act, as amended by GDUFA). The FD&C Act states, “the term ‘adjustment factor’ means a factor applicable to a fiscal year that is the Consumer Price Index for all urban consumers (all items; United States city average) for October of the preceding fiscal year divided by such Index for October 2011.”